Caption Management’s Ocular Therapeutix OCUL Stock Holding History

Caption Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,175,700	Closed	-$9.96M	–	1937
2026 Q1	$9.96M	Buy	1,175,700 +1,155,700	+5,779%	+$11M	0.06%	337
2025 Q4	$243K	Sell	20,000 -160,000	-89%	-$1.94M	﹤0.01%	1348
2025 Q3	$2.1M	Sell	180,000 -40,900	-19%	-$489K	0.02%	831
2025 Q2	$2.05M	Buy	+220,900	New	+$1.73M	0.02%	703
2024 Q4	–	Sell	-44,500	Closed	-$387K	–	1722
2024 Q3	$387K	Hold	44,500	–	–	0.01%	973
2024 Q2	$304K	Buy	+44,500	New	+$275K	﹤0.01%	897

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caption Management's OCUL Position: Q2 2026 in Review

Caption Management reduced its Ocular Therapeutix (OCUL) stake by 90% in Q2 2026, selling an estimated $3.11M and leaving 39,800 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #1375.

Caption Management first reported a position in OCUL in Q3 2019 and has held it in 7 quarters since. The position peaked at $3.24M in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Caption Management held 39,800 shares of Ocular Therapeutix worth $391K as of Q2 2026.
Caption Management sold 342,959 Ocular Therapeutix shares in Q2 2026, an estimated $3.11M.
Ocular Therapeutix made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1375 holding.
Caption Management first reported a position in Ocular Therapeutix in Q3 2019 and has held it in 7 quarters since.
Caption Management's Ocular Therapeutix position peaked at $3.24M in Q1 2026.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.